Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Middle East Pharmaceutical Industries Co EBITDA Margin %?
Middle East Pharmaceutical Industries CoSAU:4016 +0.92%22 EBITDA Margin % is 27.60% as of Mar. 2026, which is 2% above its 10-year median of 27.12. GuruFocus rates SAU:4016 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Middle East Pharmaceutical Industries Co ranks better than 83% on this metric.
Middle East Pharmaceutical Industries Co (SAU:4016) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Middle East Pharmaceutical Industries Co EBITDA Margin % Related Terms
Middle East Pharmaceutical Industries Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co EBITDA Margin % Chart
Middle East Pharmaceutical Industries Co Annual Data
Trend
Dec23
Dec24
Dec25
EBITDA Margin %
26.64
27.12
27.89
Middle East Pharmaceutical Industries Co Quarterly Data
SAU:4016 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Middle East Pharmaceutical Industries Co EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co (SAU:4016) has a EBITDA Margin % of 27.60% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Middle East Pharmaceutical Industries Co and its competitors. This is near median its historical median of 27.12. Over the past decade, Middle East Pharmaceutical Industries Co's EBITDA Margin % has ranged from 26.64 to 27.89. According to the industry distribution chart, Middle East Pharmaceutical Industries Co ranks #163 out of 959 companies in the Drug Manufacturers industry, placing it in the top 17%.
Is Middle East Pharmaceutical Industries Co's EBITDA Margin % too high?
Middle East Pharmaceutical Industries Co's current EBITDA Margin % of 27.60% is near median its 10-year median of 27.12. Over the past 10 years, this metric has ranged from a low of 26.64 to a high of 27.89. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Middle East Pharmaceutical Industries Co's value of 27.60% is 120.1% above this industry median. Based on the distribution chart, Middle East Pharmaceutical Industries Co ranks #163 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Middle East Pharmaceutical Industries Co ranks #163 out of 959 companies for EBITDA Margin %. This places Middle East Pharmaceutical Industries Co in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.54. Middle East Pharmaceutical Industries Co's value of 27.60% is 120.1% above this benchmark. Historically, Middle East Pharmaceutical Industries Co's own EBITDA Margin % has ranged from 26.64 to 27.89 over the past decade. While the company's 10-year median is 27.12 vs. the industry median of 12.54, Middle East Pharmaceutical Industries Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Middle East Pharmaceutical Industries Co's current EBITDA Margin % of 27.60% is 120.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Middle East Pharmaceutical Industries Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Middle East Pharmaceutical Industries Co's current EBITDA Margin % is 27.60%, which is near median its own 10-year median of 27.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current EBITDA Margin % of 27.60%. The current EBITDA Margin % is 27.60%, which is near median its 10-year median of 27.12 and 120.1% above the Drug Manufacturers industry median of 12.54. Middle East Pharmaceutical Industries Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current EBITDA Margin % is 27.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Middle East Pharmaceutical Industries Co Business Description
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
22GF Score
Get the complete analysis for SAU:4016
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4016 has been successfully added to your 
